Lupin and Schering-Plough settle suit over Clarinex
This article was originally published in Scrip
Executive Summary
Lupinhas settled all ongoing Hatch-Waxman litigation over desloratadine tablets, a generic version ofSchering-Plough's anti-allergic, Clarinex, tablets. As per the terms of the settlement, Lupin will be licensed under the relevant desloratadine patents, and can commercially launch its generic desloratadine on July 1st, 2012, or earlier in certain circumstances.